Not applicableLooking for participantsNCT05945732
What this trial is testing
DESTINY Breast Respond HER2-(Ultra)Low Europe
Who this might be right for
Unresectable Breast CancerMetastatic Breast CancerHER2-low Expressing Breast Cancer+1 more
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company 2,295